Trying to understand differing results of FIRE-3 and 80405: Does the first treatment matter more than others?

Journal of Clinical Oncology

Volumn 33, Issue 32, 2015, Pages 3686-3688

  O'Neil, Bert H ^a   Venook, Alan P ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; REGORAFENIB; ANTINEOPLASTIC AGENT; ONCOPROTEIN; RAS PROTEIN;

CANCER PATIENT; CANCER THERAPY; COLORECTAL CANCER; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; COLORECTAL NEOPLASMS; FEMALE; GENETICS; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84947460453     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.8495     Document Type: Review

References (17)

1. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
2. Douillard JY, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023-1034, 2013
3. De Roock W, Claes B, Bernasconi D, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 11:753-762, 2010
4. National Comprehensive Cancer Network (NCCN): NCCN Guidelines for Treatment of Metastatic Colorectal Cancer. Fort Washington, PA, NCCN, 2015
5. Van Cutsem E, Cervantes A, Nordlinger B, et al: Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:iii1-9, 2014 (suppl 3)
6. Goldberg RM, Rothenberg ML, Van Cutsem E, et al: The continuum of care: A paradigm for the management of metastatic colorectal cancer. Oncologist 12:38-50, 2007
7. Modest DP, Stintzing S, Fischer von Weikersthal L, et al: Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: First-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J Clin Oncol 33:3718-3726, 2015
8. Heinemann V, von Weikersthal LF, Decker T, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomized, open-label, phase 3 trial. Lancet Oncol 15:1065-1075, 2014
9. Shi Q, de Gramont A, Grothey A, et al: Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: Findings from the analysis and research in cancers of the digestive system database. J Clin Oncol 33:22-28, 2015
10. Modest DP, Stintzing S, Fischer Von Weikersthal L, et al: Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial. J Clin Oncol 32:227s, 2014 (abstr 3558)
11. Grothey A, Sugrue M, Hedrick E, et al: Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE). J Clin Oncol 25:172s, 2007 (abstr 4036)
12. Grothey A, Sugrue MM, Purdie DM, et al: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326-5334, 2008
13. Bennouna J, Sastre J, Arnold D, et al: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomized phase 3 trial. Lancet Oncol 14:29-37, 2013
14. Tabernero J, Cohn AL, Obermannova R, et al: RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J Clin Oncol 33, 2015 (suppl; abstr 512)
15. Van Cutsem E, Tabernero J, Lakomy R, et al: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499-3506, 2012
16. Loupakis F, Cremolini C, Masi G, et al: Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371:1609-1618, 2014
17. Fuchs CS, Marshall J, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study. J Clin Oncol 25:4779-4786, 2007